174 related articles for article (PubMed ID: 36918828)
21. PTEN mutation: A potential prognostic factor associated with immune infiltration in endometrial carcinoma.
Tao Y; Liang B
Pathol Res Pract; 2020 Jun; 216(6):152943. PubMed ID: 32279917
[TBL] [Abstract][Full Text] [Related]
22. TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
D'Alessandris N; Travaglino A; Santoro A; Arciuolo D; Scaglione G; Raffone A; Inzani F; Zannoni GF
Gynecol Oncol; 2021 Nov; 163(2):427-432. PubMed ID: 34446267
[TBL] [Abstract][Full Text] [Related]
23. Combination of Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer.
Eriksson LSE; Nastic D; Lindqvist PG; Imboden S; Järnbert-Pettersson H; Carlson JW; Epstein E
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):457-468. PubMed ID: 33314410
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of metformin in the treatment of estrogen-dependent endometrial carcinoma complicated with type 2 diabetes mellitus and analysis of its prognosis.
Deng Y; Wang J; Li W; Xiong W; Wang X
J BUON; 2020; 25(3):1534-1540. PubMed ID: 32862601
[TBL] [Abstract][Full Text] [Related]
25. Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.
Proctor L; Pradhan M; Leung S; Cheng A; Lee CH; Soslow RA; Gilks CB; Talhouk A; McAlpine JM; Danielsen HE; Hoang LN
Gynecol Oncol; 2017 Sep; 146(3):596-602. PubMed ID: 28647100
[TBL] [Abstract][Full Text] [Related]
26. Expression of ER, PR, C-erbB-2 and Ki-67 in Endometrial Carcinoma and their Relationships with the Clinicopathological Features.
Yu CG; Jiang XY; Li B; Gan L; Huang JF
Asian Pac J Cancer Prev; 2015; 16(15):6789-94. PubMed ID: 26434913
[TBL] [Abstract][Full Text] [Related]
27. Vimentin Protein In Situ Expression Predicts Less Tumor Metastasis and Overall Better Survival of Endometrial Carcinoma.
Zhang X; Cao G; Diao X; Bai W; Zhang Y; Wang S
Dis Markers; 2022; 2022():5240046. PubMed ID: 35320951
[TBL] [Abstract][Full Text] [Related]
28. Differential impact of clinicopathological risk factors within the 2 largest ProMisE molecular subgroups of endometrial carcinoma.
Pasanen A; Loukovaara M; Ahvenainen T; Vahteristo P; Bützow R
PLoS One; 2021; 16(9):e0253472. PubMed ID: 34473724
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
Pasanen A; Ahvenainen T; Pellinen T; Vahteristo P; Loukovaara M; Bützow R
Am J Surg Pathol; 2020 Feb; 44(2):174-181. PubMed ID: 31651527
[TBL] [Abstract][Full Text] [Related]
30. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
Stelloo E; Nout RA; Osse EM; Jürgenliemk-Schulz IJ; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Nijman HW; Putter H; Bosse T; Creutzberg CL; Smit VT
Clin Cancer Res; 2016 Aug; 22(16):4215-24. PubMed ID: 27006490
[TBL] [Abstract][Full Text] [Related]
31. [Using Immunohistochemical Markers and Clinicopathological Factors to Predict the Prognostic Survival of Different Types of Endometrial Cancer Recurrence].
Huang Z; Jiang P; Jia MZ; Li L; Deng Y; Lai L; Hu ZY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 May; 52(3):489-496. PubMed ID: 34018370
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification.
Karnezis AN; Leung S; Magrill J; McConechy MK; Yang W; Chow C; Kobel M; Lee CH; Huntsman DG; Talhouk A; Kommoss F; Gilks CB; McAlpine JN
J Pathol Clin Res; 2017 Oct; 3(4):279-293. PubMed ID: 29085668
[TBL] [Abstract][Full Text] [Related]
33. Decreased expression of TFAP2B in endometrial cancer predicts poor prognosis: A study based on TCGA data.
Wu H; Zhang J
Gynecol Oncol; 2018 Jun; 149(3):592-597. PubMed ID: 29602546
[TBL] [Abstract][Full Text] [Related]
34. The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: a meta-analysis based on 49 articles incorporating 12,120 patients.
Wu Q; Zhang N; Xie X
BMC Cancer; 2022 Nov; 22(1):1157. PubMed ID: 36357827
[TBL] [Abstract][Full Text] [Related]
35. [Clinical application of adult comorbidity evaluation-27 in endometrial cancer].
Tian WY; Wang YM; Yan Y; Gao JP; Sun DD; Jiang S; Sheng Y; Teng F; Xue FX
Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):810-817. PubMed ID: 27916063
[No Abstract] [Full Text] [Related]
36. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.
Britton H; Huang L; Lum A; Leung S; Shum K; Kale M; Burleigh A; Senz J; Yang W; McConechy M; Kommoss S; Brucker S; Talhouk A; Gilks CB; McAlpine JN
Gynecol Oncol; 2019 Jun; 153(3):487-495. PubMed ID: 30922603
[TBL] [Abstract][Full Text] [Related]
37. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.
Jumaah AS; Al-Haddad HS; McAllister KA; Yasseen AA
PLoS One; 2022; 17(2):e0263585. PubMed ID: 35139130
[TBL] [Abstract][Full Text] [Related]
38. Naples prognostic score is an independent prognostic factor in patients with operable endometrial cancer: Results from a retrospective cohort study.
Li Q; Cong R; Wang Y; Kong F; Ma J; Wu Q; Ma X
Gynecol Oncol; 2021 Jan; 160(1):91-98. PubMed ID: 33081984
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
Vrede SW; van Weelden WJ; Visser NCM; Bulten J; van der Putten LJM; van de Vijver K; Santacana M; Colas E; Gil-Moreno A; Moiola CP; Mancebo G; Krakstad C; Trovik J; Haldorsen IS; Huvila J; Koskas M; Weinberger V; Bednarikova M; Hausnerova J; van der Wurff AA; Matias-Guiu X; Amant F; ; Snijders MPLM; Küsters-Vandevelde HVN; Reijnen C; Pijnenborg JMA
Gynecol Oncol; 2021 Jun; 161(3):787-794. PubMed ID: 33858677
[TBL] [Abstract][Full Text] [Related]
40. TCGA molecular groups of endometrial cancer: Pooled data about prognosis.
Raffone A; Travaglino A; Mascolo M; Carbone L; Guida M; Insabato L; Zullo F
Gynecol Oncol; 2019 Nov; 155(2):374-383. PubMed ID: 31472940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
